H.C. Wainwright analyst Ed Arce maintained a Buy rating on Genfit SA (GNFT) today and set a price target of $72. The company’s shares opened today at $25.03.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 11.2% and a 39.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genfit SA with a $52 average price target, representing a 107.8% upside. In a report issued on April 16, B.Riley FBR also reiterated a Buy rating on the stock with a $52 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.08 and a one-year low of $20.32. Currently, Genfit SA has an average volume of 340.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments.
